CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial

LAS VEGAS, Jan. 8 /PRNewswire-FirstCall/ — CardioVascular
BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two
additional hospitals in the United States opened for patient enrollment for
its ACORD Phase II clinical trial for the treatment of severe coronary heart
disease. The sites are University of California Medical Center San Diego, CA
and Holy Cross Hospital, Fort Lauderdale, FL.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati,
Ohio were first to open for enrollment in early September, and are working in
collaboration to screen and treat patients in the trial. They treated their
first patient in support of the trial in mid November 2008.

CVBT now has five sites that are open for enrollment and intends to
announce additional sites as they open for screening patents.

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1
for cardiovascular diseases characterized by inadequate blood flow to a tissue
or organ. In addition to the Phase II trial it is conducting in patients with
severe coronary heart disease, the company has two FDA-authorized clinical
trials in the areas of impaired wound healing seen in diabetics and in
patients suffering from peripheral artery disease of the legs. An additional
study is being conducted in patients with chronic back pain who may have
perfusion defects to their spine. For more information about CardioVascular
BioTherapeutics, Inc. please visit http://www.cvbt.com.

     Media Contact:
     Allison Caplan,
     CardioVascular BioTherapeutics, Inc.
     (702) 839-7200, acaplan@cvbt.com

     Investor Contact:
     Amy Montano Gordon,
     CardioVascular BioTherapeutics, Inc.
     (702) 839-7220, investorrelations@cvbt.com

SOURCE CardioVascular BioTherapeutics, Inc.